Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore

Wai-Sze-Agnes CHAN; Yisheng WONG; Hazel-Hwee-Boon OON; Colin-Thiam-Seng THENG; Wei-Sheng CHONG.
Singapore medical journal ; : 434-438, 2023.
Artículo en Inglés | WPRIM | ID: wpr-984205

Documentos relacionados

  1. Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore.
  2. Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis.
  3. Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS).
  4. Improving categorical endpoint longitudinal exposure-response modeling through the joint modeling with a related endpoint.
  5. Early Response is Associated With Stable Long-Term Response in Psoriasis Patients Receiving Ixekizumab or Ustekinumab.
  6. Network meta-analyses in psoriasis: overview and critical discussion.
  7. Ustekinumab to guselkumab transitions: A series of 54 patients emulating the navigate trial in real life.
  8. Predictors of time to relapse following ustekinumab withdrawal in patients with psoriasis who had responded to therapy: An 8-year multicenter study.
  9. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
  10. Clinical features, therapeutic choice and response by phototype in psoriasis: analysis of the French PsoBioTeq cohort.